Gilead sours on the ‘don’t eat me’ business

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.

The need-to-know this morning

• AstraZeneca reported fourth quarter and 2023 earnings.
• BioNTech and Autolus announced a CAR-T cell therapy partnership.
• Kyverna Therapeutics, a developer of cell therapies for autoimmune diseases, priced its IPO at $22 per share, raising $319 million.
• The Phase 3 study of resmetirom, a treatment for MASH made by Madrigal Pharmaceuticals, was published in the New England Journal of Medicine.

Pharma returns to Washington

Sen. Bernie Sanders, who all but séanced Frederick Banting to scold the CEO of Eli Lilly and tried to sell Moderna’s Stéphane Bancel on nationalizing pharmaceutical research, will again play haranguing host to drug industry executives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In